Ontology type: schema:ScholarlyArticle
2017-06
AUTHORSKumar Kandadi Muralidharan, Deb Steiner, Diogo Amarante, Pei-Ran Ho, Dan Mikol, Jacob Elkins, Meena Subramanyam, Ivan Nestorov
ABSTRACTNatalizumab, a human immunoglobulin monoclonal antibody that targets α4β1/α4β7 integrin, is an effective therapy approved for the treatment of multiple sclerosis (MS). The objective of this analysis was to develop a population exposure-response model utilizing gadolinium-enhancing (Gd) lesion count data from four clinical studies and annualized relapse rate (ARR) data from three clinical studies. The natalizumab exposures were derived for the individuals using a population pharmacokinetic model. A log-linear exposure effect on Gd lesion count and ARR adequately characterized the relationship between exposure and disease response. In the case of the Gd lesion count model, a bimodal model that distributed subjects into two subpopulations based on low or high baseline Gd lesion count provided a superior goodness of fit. The mean (95% confidence interval) slopes from the exposure-Gd lesion count model and exposure-ARR model are -0.0903 (-0.100, -0.081) and -0.0222 (-0.026, -0.015) (mg/L)-1, respectively. From these slopes, it can be inferred that both Gd lesion count and ARR decrease with increasing exposure to natalizumab in MS subjects. Model-based simulations demonstrated that although reductions in Gd lesion count and ARR were observed with lower doses (75, 150, or 200 mg), only the dose of 300 mg every 4 weeks (q4w) was associated with an ARR ≤0.25 and was considered clinically effective. The results from the exposure-Gd lesion count and exposure-ARR models thus support the appropriateness of the approved natalizumab dose (300 mg q4w) in MS subjects. More... »
PAGES263-275
http://scigraph.springernature.com/pub.10.1007/s10928-017-9514-4
DOIhttp://dx.doi.org/10.1007/s10928-017-9514-4
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1084028043
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/28251386
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Public Health and Health Services",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adolescent",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Antibodies, Monoclonal, Humanized",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Clinical Trials as Topic",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Female",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gadolinium",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Male",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Middle Aged",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Multiple Sclerosis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Natalizumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Recurrence",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Treatment Outcome",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Young Adult",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Systems Pharmacology, Biogen, 14 Cambridge Center, 02142, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Muralidharan",
"givenName": "Kumar Kandadi",
"id": "sg:person.016145406501.06",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016145406501.06"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Clinical Development, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Steiner",
"givenName": "Deb",
"id": "sg:person.014424656727.95",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014424656727.95"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Global Medical Affairs, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Amarante",
"givenName": "Diogo",
"id": "sg:person.013710434501.18",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013710434501.18"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Global Medical Affairs, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Ho",
"givenName": "Pei-Ran",
"id": "sg:person.015126524421.85",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015126524421.85"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Clinical Development, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Mikol",
"givenName": "Dan",
"id": "sg:person.016615200327.27",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016615200327.27"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Clinical Development, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Elkins",
"givenName": "Jacob",
"id": "sg:person.0632630700.05",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632630700.05"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Global Biomarker Discovery and Development, Biogen, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Subramanyam",
"givenName": "Meena",
"id": "sg:person.01052004072.92",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052004072.92"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Biogen (United States)",
"id": "https://www.grid.ac/institutes/grid.417832.b",
"name": [
"Systems Pharmacology, Biogen, 14 Cambridge Center, 02142, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Nestorov",
"givenName": "Ivan",
"id": "sg:person.0731542654.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0731542654.93"
],
"type": "Person"
}
],
"citation": [
{
"id": "https://doi.org/10.1016/j.cmpb.2005.04.005",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1006146346"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1371/journal.pone.0073361",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1022653676"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/sim.4780130509",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028066263"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa020696",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1028601929"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1586/14737175.4.4.571",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029452571"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1212/wnl.0000000000000355",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029638249"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1212/wnl.0000000000000355",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1029638249"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/sim.2108",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032910450"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/sim.2108",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1032910450"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ana.21606",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034711830"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/ana.21606",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1034711830"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00415-015-7655-1",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035229942",
"https://doi.org/10.1007/s00415-015-7655-1"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1002/sim.4394",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1035640805"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10928-016-9477-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038397873",
"https://doi.org/10.1007/s10928-016-9477-x"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s10928-016-9477-x",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1038397873",
"https://doi.org/10.1007/s10928-016-9477-x"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa044396",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047160581"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1056/nejmoa044397",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1047413416"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1155/2014/262350",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1051162825"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1038/psp.2014.27",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053267332"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1136/jnnp-2015-312940",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1053308260"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1212/01.wnl.0000158329.30470.d0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064346988"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1212/01.wnl.0000158329.30470.d0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064346988"
],
"type": "CreativeWork"
},
{
"id": "https://doi.org/10.1212/01.wnl.0000158329.30470.d0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1064346988"
],
"type": "CreativeWork"
},
{
"id": "https://app.dimensions.ai/details/publication/pub.1078186101",
"type": "CreativeWork"
}
],
"datePublished": "2017-06",
"datePublishedReg": "2017-06-01",
"description": "Natalizumab, a human immunoglobulin monoclonal antibody that targets \u03b14\u03b21/\u03b14\u03b27 integrin, is an effective therapy approved for the treatment of multiple sclerosis (MS). The objective of this analysis was to develop a population exposure-response model utilizing gadolinium-enhancing (Gd) lesion count data from four clinical studies and annualized relapse rate (ARR) data from three clinical studies. The natalizumab exposures were derived for the individuals using a population pharmacokinetic model. A log-linear exposure effect on Gd lesion count and ARR adequately characterized the relationship between exposure and disease response. In the case of the Gd lesion count model, a bimodal model that distributed subjects into two subpopulations based on low or high baseline Gd lesion count provided a superior goodness of fit. The mean (95% confidence interval) slopes from the exposure-Gd lesion count model and exposure-ARR model are -0.0903 (-0.100, -0.081) and -0.0222 (-0.026, -0.015)\u00a0(mg/L)-1, respectively. From these slopes, it can be inferred that both Gd lesion count and ARR decrease with increasing exposure to natalizumab in MS subjects. Model-based simulations demonstrated that although reductions in Gd lesion count and ARR were observed with lower doses (75, 150, or 200\u00a0mg), only the dose of 300\u00a0mg every 4\u00a0weeks (q4w) was associated with an ARR \u22640.25 and was considered clinically effective. The results from the exposure-Gd lesion count and exposure-ARR models thus support the appropriateness of the approved natalizumab dose (300\u00a0mg q4w) in MS subjects.",
"genre": "research_article",
"id": "sg:pub.10.1007/s10928-017-9514-4",
"inLanguage": [
"en"
],
"isAccessibleForFree": false,
"isPartOf": [
{
"id": "sg:journal.1016394",
"issn": [
"1567-567X",
"2168-5789"
],
"name": "Journal of Pharmacokinetics and Pharmacodynamics",
"type": "Periodical"
},
{
"issueNumber": "3",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "44"
}
],
"name": "Exposure\u2013disease response analysis of natalizumab in subjects with multiple sclerosis",
"pagination": "263-275",
"productId": [
{
"name": "readcube_id",
"type": "PropertyValue",
"value": [
"7f41ddbf71191528bf936eaf77512d73fe5ce3eb87a89d2b47fe6d2d41e98378"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"28251386"
]
},
{
"name": "nlm_unique_id",
"type": "PropertyValue",
"value": [
"101096520"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1007/s10928-017-9514-4"
]
},
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1084028043"
]
}
],
"sameAs": [
"https://doi.org/10.1007/s10928-017-9514-4",
"https://app.dimensions.ai/details/publication/pub.1084028043"
],
"sdDataset": "articles",
"sdDatePublished": "2019-04-11T10:02",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000347_0000000347/records_89822_00000002.jsonl",
"type": "ScholarlyArticle",
"url": "https://link.springer.com/10.1007%2Fs10928-017-9514-4"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10928-017-9514-4'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10928-017-9514-4'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10928-017-9514-4'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10928-017-9514-4'
This table displays all metadata directly associated to this object as RDF triples.
236 TRIPLES
21 PREDICATES
62 URIs
36 LITERALS
24 BLANK NODES